Investigators ascertained a pedigree from the Canary Islands in which six siblings experienced chronic, high-dose pesticide exposure. Three siblings developed levodopa-responsive, akinetic-rigid Parkinson's disease (PD) while the remaining three siblings remained clinically unaffected. Whole-exome sequencing performed on the three affected siblings identified a heterozygous VPS35 p.A320V (c.959C>T) variant present in all affected individuals and absent in the three unaffected siblings. The variant had previously been described as of unknown significance in two late-onset sporadic PD patients.
To estimate prevalence beyond the pedigree, the study assessed the frequency of the p.A320V variant in a combined case-control dataset drawn from four independent cohorts. Across 23,327 PD patients and 9,235 controls, p.A320V was detected in six PD patients and in one control. The source reports these counts but does not provide additional population frequencies, odds ratios, or statistical significance metrics in the manuscript text.
Prior work established that the pathogenic VPS35 p.D620N variant activates the LRRK2 kinase pathway, producing increased phosphorylation of Rab GTPase substrates measurable in peripheral immune cells. In the present study, members of the pedigree and unrelated controls were assessed for LRRK2 kinase activity in monocytes and neutrophils. Unlike the p.D620N signature, heterozygous carrier status for p.A320V was not associated with increased LRRK2 kinase activity in these immune-cell assays according to the reported results.
Elevated urinary bis(monoacylglycero)phosphate (BMP) levels have been reported in carriers of VPS35 p.D620N. The study measured urine BMP in pedigree members and controls to test whether p.A320V carriers shared this biochemical signature. The manuscript reports that p.A320V carriers did not show elevated urine BMP levels relative to expectations from p.D620N carriers. No additional quantitative BMP values or statistical tests are provided in the article text.
Whole-exome sequencing was performed on the three affected siblings in the Canary Islands family to identify candidate variants. The candidate variant frequency was then evaluated in a combined cohort totaling 23,327 PD patients and 9,235 controls compiled from four independent sources. The investigators performed LRRK2 kinase activity assays in monocytes and neutrophils and measured urine BMP concentrations in pedigree members and unrelated controls. The manuscript states these experimental approaches but does not include detailed protocols, assay parameters, or full numerical results beyond the summary comparisons reported.
The principal finding is that VPS35 p.A320V co-segregated with PD in this pesticide-exposed family: all three affected siblings were heterozygous for the variant and the three unaffected siblings did not carry it. However, the variant did not reproduce the LRRK2-associated biomarker signature characteristic of VPS35 p.D620N carriers — specifically, increased LRRK2 kinase activity in peripheral immune cells and elevated urine BMP were absent for p.A320V carriers in the reported assays.
The authors suggest two non–mutually exclusive interpretations consistent with the reported data: (1) p.A320V may exert a subtle effect on VPS35 function that was not captured by the assays performed, and (2) chronic pesticide exposure in the family may have contributed to disease penetrance in carriers of a variant with limited standalone pathogenicity. The manuscript does not claim definitive pathogenicity for p.A320V and acknowledges the absence of the biomarker profile seen with a known pathogenic VPS35 variant.
The study reports institutional review board approvals from multiple centers, including the IRBs of University Fernando Pessoa-Canarias, University of Navarra, Veterans Affairs Puget Sound Healthcare System, University of Luebeck, and University of Vienna. The authors confirm that participant consent was obtained and that data produced in the present work are contained in the manuscript. Declared funders include the Michael J. Fox Foundation (MJFF) and the United States Department of Veterans Affairs. Competing interests disclosed by authors are reported in the source.
Concluding summary
In this family with documented chronic pesticide exposure, VPS35 p.A320V segregated with PD phenotype among siblings but did not associate with the LRRK2-activation and urine BMP biomarker profile characteristic of the established pathogenic p.D620N variant. The findings raise the possibility that p.A320V has a subtle or context-dependent effect on VPS35 function and that environmental exposure may modify penetrance; however, the assays performed did not demonstrate the canonical biochemical alterations observed with established VPS35-associated PD. The manuscript contains the data reported here; additional functional studies or larger population analyses would be required to clarify pathogenicity and mechanism, but such data were not provided in the source.